Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04KBL
|
|||
| Former ID |
DIB016123
|
|||
| Drug Name |
Bevacizumab
|
|||
| Synonyms |
Bevacizumab (ophthalmic slow-release tissue tablet)
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Metastatic colorectal cancer [ICD-11: 2B91; ICD-10: C19] | Approved | [1] | |
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 3 | [2], [3] | ||
| Brain metastases [ICD-11: 2D50; ICD-10: C79.3; ICD-9: 198.3] | Phase 2 | [2] | ||
| Lung cancer [ICD-11: 2C25.0; ICD-9: 162] | Phase 1 | [2] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [2], [3] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Application submitted | [3] | ||
| Company |
University of London
|
|||
| ADReCS Drug ID | BADD_D00268 | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.